http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Sharma Meha (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Deep Dutta,Ritin Mohindra,Kunal Mahajan,Meha Sharma 대한당뇨병학회 2023 Diabetes and Metabolism Journal Vol.47 No.1
Background: No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events.Results: Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], –1.35 mmol/L; 95% confidence interval [CI], –1.72 to –0.98; <i>P</i><0.01; I<sup>2</sup>=63%) and 2hPPG (MD, –1.19 mmol/L; 95% CI, –1.38 to –1.00; <i>P</i><0.01; I<sup>2</sup>=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, –3.84 to 5.96; <i>P</i>=0.67; I<sup>2</sup>=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, –0.91%; 95% CI, –1.84 to 0.03; <i>P</i>=0.06; I<sup>2</sup>=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; <i>P</i>=0.51; I<sup>2</sup>=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; <i>P</i>=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; <i>P</i>=0.77; I<sup>2</sup>=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; <i>P</i>=0.50; I<sup>2</sup>=0%) were comparable.Conclusion: FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.
-
Nagendra Lakshmi,Dutta Deep,Girijashankar Harish Bukkasagar,Khandelwal Deepak,Lathia Tejal,Sharma Meha 대한소아내분비학회 2024 Annals of Pediatirc Endocrinology & Metabolism Vol.29 No.2
Purpose: Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been evaluated in children with type 2 diabetes mellitus (T2DM), type 1 diabetes mellitus (T1DM), and several other nondiabetic conditions. Potential tolerability issues have prevented the routine use of SGLT2i in children with diabetes. However, no meta-analysis to date has evaluated the safety and tolerability of SGLT2i in children. This systematic review and meta-analysis aimed to address this knowledge gap.Methods: Databases were searched for randomized controlled trials (RCTs), case control, and cohort studies involving children receiving SGLT2i in the intervention-arm. Primary outcome was occurrence of treatment emergent adverse events (TAEs). Secondary outcomes were evaluation of glycemic efficacy and occurrence of severe adverse events (SAEs), hypoglycemia, ketosis, genital or urinary infections, and any other adverse events.Results: From the 27 articles initially screened, data from 4 RCTs (258 children) were analyzed. In children with T2DM, occurrence of TAEs (odds ratio [OR], 1.77; 95% confidence interval [CI], 0.93–3.36; <i>P</i>=0.08; <i>I</i><sup>2</sup>=0%), SAEs (OR, 0.45; 95% CI, 0.08–2.54; <i>P</i>=0.37; <i>I</i><sup>2</sup>=0%), ketoacidosis (OR, 0.33; 95% CI, 0.01–8.37; <i>P</i>=0.50), urinary tract infections (OR, 2.34; 95% CI, 0.44–12.50; <i>P</i>=0.32; <i>I</i><sup>2</sup>=0%), and severe hypoglycemia (OR, 4.47; 95% CI, 0.21–96.40; <i>P</i>=0.34) were comparable among the SGLTi group and placebo. Compared to placebo, T2DM children receiving SGLTi had significantly lower glycosylated hemoglobin at 24–26 weeks (mean difference [MD], -0.79%; 95% CI, -1.33 to -0.26; <i>P</i>=0.004; <i>I</i><sup>2</sup>=0%). In T1DM children, β-hydroxybutyrate levels were significantly higher in the SGLTi group than the placebo group (MD, 0.11 mmol/L; 95% CI, 0.05–0.17; <i>P</i>=0.0005; <i>I</i><sup>2</sup>=53%). In T1DM, there was not a single report of an SAE, ketoacidosis, or severe hypoglycemia in either the placebo or treatment groups, but time-in-range was considerably greater in the SGLT2i group than the placebo group (68%±6% vs. 50%±13%, <i>P</i><0.001).Conclusion: SGLT2i use in children and young adults appears to be both safe and tolerable based on our meta-analyses and review of the literature.
-
Deep Dutta,Anshita Agarwal,Indira Maisnam,Rajiv Singla,Deepak Khandelwal,Meha Sharma 대한내분비학회 2021 Endocrinology and metabolism Vol.36 No.2
Background: No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap. Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobinA1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events. Results: Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin ascontrols. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I2=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI,–1.18 to –0.63); P<0.01; I2=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c<7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I2=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60;P<0.01; I2=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI,0.52 to 1.63; P=0.77; I2=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR],1.06; 95% CI, 0.82 to 1.36; P=0.66; I2=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95%CI, 0.62 to 2.28; P=0.61; I2=19%; HCE). Conclusion: Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
